A Clot from a Sixteen-Hour Flight, and a Thrombophilia Result That Complicates the Simple Answer
His DVT looks like a textbook travel-provoked clot until the thrombophilia panel comes back positive — and the guidelines were never built to say clearly which fact should decide how long he stays on a blood thinner.
P.D., a 41-year-old software consultant, flew sixteen hours home from a work trip — working from his laptop the whole way and, by his own unprompted account, getting up exactly once, the kind of unbroken immobility that makes the flight a genuine provoking factor rather than a coincidence of timing — and noticed his left calf swelling and aching two days later, bad enough by day three that he went to urgent care and was found on ultrasound to have a proximal deep vein thrombosis. He had no prior VTE, no recent surgery, no immobilization beyond the flight itself, no active malignancy, and no hormonal medications — a presentation that, on its own, fits cleanly into the minor-transient-provoking-factor category the CHEST (American College of Chest Physicians) antithrombotic guidelines are built around, generally pointing toward a standard three-month course rather than extended or indefinite anticoagulation.
A thrombophilia panel, sent somewhat reflexively given his relatively young age and the specific request of an anxious family member, came back positive for heterozygous Factor V Leiden — a finding that complicates rather than clarifies the duration question. Current duration-of-therapy frameworks classify events primarily by the strength of the provoking factor, and a long-haul flight sits in the minor-provoking-factor category regardless of thrombophilia status; heterozygous Factor V Leiden by itself is a real but modest risk factor that most guidance does not treat as strong enough, alone, to override a minor-provoked classification and push toward extended anticoagulation. The team's actual disagreement is whether that guideline framework is being applied correctly here, or whether it understates a genuinely elevated recurrence risk once both factors are present together.
In follow-up, once the thrombophilia result came back
His presentation fits the minor-provoking-factor category cleanly — a long flight, symptoms shortly after, no other risk factors present. Current duration guidelines classify primarily by how strong the provoking factor was, and heterozygous Factor V Leiden on its own isn't treated as strong enough to move him out of that category. I'd recommend the standard three-month course.
I understand the guideline logic, but I'd want us to think about the combination directly rather than each factor separately — a real provoking event plus a real, if modest, underlying thrombophilia together plausibly carries more recurrence risk than either alone. His family is anxious, understandably, and I don't think 'the framework wasn't built for two factors at once' is a fully satisfying answer to give them.
The category boundaries feel almost designed for a cleaner, single-factor case than his — that's a real gap worth naming, not dismissing.
I'd push back gently on calling this an unreviewed gap — this exact combination, a minor provoking event plus heterozygous Factor V Leiden, has specifically been considered by the guideline committees that built these duration frameworks, and they still did not recommend extension. That's not an oversight to correct informally at the bedside; it's a considered judgment based on the actual recurrence data available.
I'd stay with the standard three-month course, and be direct with him and his family about why — not because the thrombophilia doesn't matter at all, but because the best available evidence doesn't support extending duration on its strength alone in a case shaped like his.
Agreed: standard three-month course of apixaban, with the reasoning explained directly to him and his family — the combination was genuinely considered, not overlooked, and the evidence available does not support extending duration on the thrombophilia result alone. A written situational-prophylaxis plan for future long-haul travel was given regardless of today's duration decision.